UroGen Pharma Ltd.'s (NASDAQ: URGN) third quarter financial results release is scheduled for Wednesday 6th November 2024, before the market opens. Investors and analysts will be able to assess the company's performance during the quarter.
the organization is poised to announce an estimated $0.82 loss per share for the quarter, as predicted by financial experts on Wall Street. Additionally, the firm is expected to reveal a total revenue of $24.2 million for this period.
Wall Street analysts have revealed their forecasts for the company's annual performance, predicting a total revenue of $93.06 million. Additionally, they expect the company to report per share loss of $3.36 for the fiscal year.
When examining the earnings report from the corresponding quarter of the previous year, it is evident that the company showcased per-share loss of $0.68. This numbers can be credited to the company's total revenue, which amounted to an impressive $20.85 million during the same quarter.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-0.91 | +11.7% | 21.85 M | +3.4% |
| Q1 2024 | $-0.97 | +25.4% | 18.78 M | +9.2% |
| Q4 2023 | $-0.72 | +41.0% | 23.53 M | +30.1% |
| Q3 2023 | $-0.68 | +39.8% | 20.85 M | +29.5% |
| Q2 2023 | $-1.03 | +12.7% | 21.14 M | +27.3% |
| *Growth on year-over-year basis | ||||
Additionally, The company will host a conference call with investors and analysts on 6th November 2024 at 10:00 AM eastern time to review the Q3 2024 financial results.
UroGen Pharma Ltd. (URGN) closed Friday's regular trading session at $12.20, indicating a 0.49 percent decrease. During the day, URGN shares traded between $12.07 and $12.66, with a day volume of 595.60 thousand shares.
